Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 7/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | LPL | P06858 | 7/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9964929 | 0.81 | DGAT1 (0.37) | DGAT1LPLLIPGIRAK4FFAR1 | |
| SCHEMBL12471470 | 0.80 | NOTUM (0.49) | KCNJ1LPLLIPG | |
| SCHEMBL31078304 | 0.78 | MAPT (0.40) | DGAT1LPLLIPGIRAK4FFAR1 | |
| SCHEMBL595299 | 0.78 | MAPT (0.40) | DGAT1LPLLIPGIRAK4FFAR1 | |
| SCHEMBL13430107 | 0.77 | DGAT1 (0.39) | KCNJ1DGAT1LPLLIPGIRAK4 | |
| SCHEMBL13430003 | 0.76 | DGAT1 (0.38) | DGAT1LPLLIPGIRAK4FFAR1 | |
| SCHEMBL860013 | 0.75 | LMNA (0.46) | DGAT1LPLLIPGIRAK4FFAR1 | |
| SCHEMBL13429918 | 0.75 | IRAK4 (0.39) | DGAT1LPLLIPGIRAK4FFAR1 | |
| SCHEMBL13429621 | 0.74 | IRAK4 (0.39) | DGAT1LPLLIPGIRAK4FFAR1 | |
| SCHEMBL1927105 | 0.74 | KDM4E (0.44) | DGAT1LPLLIPGIRAK4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| EP-2134721-A1 | ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | Micurx Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008108988-A1 | ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008108988-A1 | ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | KCNJ1 1196/4885DGAT1 2130/4885LPL 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.